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Objectives. This study compared the safety and efficacy of 
digoxin and flecainide in the prophylaxis of supraventricular 
tachycardia in infants. 
Background. Recurrence of supraventricular tachycardia in 
infants is common. Digoxin is the conventional drug of first choice 
for prophylaxis, but its efficacy has not been tested in a controlled 
clinical trial, and there is no consensus on the drug of choice when 
digoxin is ineffective. 
Methods. We reviewed retrospectively the records of all infants 
with supraventricular tachycardia ue to atrioventrieular (AV) 
reentry admitted to our hospital between January 1986 and 
December 1993. 
Results. Thirty-nine infants presented with sustained AV reen- 
trant tachycardia at age 1 to 330 days (median 12). Intravenous 
flecainide was required to maintain immediate control in six 
patients who were then treated with oral flecainide. The other 33 
patients were treated with oral digoxin. There was no recurrence 
of tachycardia in 14 (42%) of the 33 patients (95% confidence 
interval [CI] 25% to 61%). In the other 19 patients (58%) (95% CI 
39% to 75%), digoxin was replaced by oral flecainide because of 
multiple recurrence of tachycardia. Full control was achieved in 
all 19 of these patients (100%) (95% CI 82% to 100%) and in 5 of 
the 6 patients treated with both intravenous and oral flecainide. 
Thus, overall, flecainide was effective in 24 (96%) of 25 patients 
(95% CI 80% to 100%). 
Conclusions. Comparison with previous natural history studies 
suggests that digoxin is ineffective in the prophylaxis of supraven- 
tricnlar tachycardia. Oral flecainide was effective in a small 
number of infants, with no adverse effects (95% CI 0% to 12%), 
and may now be preferred as the primary prophylactic agent. 
(J Am Coil Cardiol 1995;26:991-4) 
Supraventricular tachycardia in e rly infancy is serious and 
potentially life-threatening. Once th diagnosis is made, the 
restoration ofsinus rhythm is usually straightforward. Because 
the risk of spontaneous recurrence of tachycardia is relatively 
high (1), prophylactic treatment for all patients is usually 
recommended (2,3). The widely recommended drug of first 
choice is digoxin, but there is no standardized approach to the 
treatment ofpatients in whom digoxin s ineffective (3,4). Over 
the past 10 years there has been increasing i terest in the 
efficacy and safety of newer antiarrhythmic drugs, particularly 
those in Vaughan-Williams class IC. This retrospective study 
was performed to compare the safety and efficacy of digoxin 
and flecainide in prophylaxis of supraventricular tachycardia in 
infants. 
Methods  
The Northern health region of England serves a well 
defined population of just over 3 million. All pediatric patients 
with suspected tachycardia from15 of the 16 districts (corn- 
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bined birth rate 38,500/year) are referred to Freeman Hospital. 
We reviewed the medical records of all infants at this hospital 
with a diagnosis of supraventricular tachycardia between Jan- 
uary 1986 and December 1993. Patients with an electro- 
cardiographic (ECG) diagnosis of atrial flutter, ectopic atrial 
tachycardia, His bundle tachycardia (junctional ectopic tachy- 
cardia), permanent junctional reentrant tachycardia orchaotic 
atrial tachycardia were excluded. The diagnosis of orthodromic 
atrioventricular (AV) reentry was based on a 12-lead ECG and 
was defined as a tachycardia with a normal QRS complex, no 
evi ence of AV dissociation and a ventriculoarterial interval 
(RP interval) >70 ms (5). The permanent form of junctional 
reciprocating tachycardia is also a type of AV reentry and was 
recognized by a long RP interval, inverted P waves in inferior 
leads and incessant behavior. Patients with this arrhythmia 
were excluded. Although no infant had an electrophysiologic 
study, ECG diagnosis of orthodromic AV reentry is accurate 
and reliable in this age group. Previous reports (5,6) have 
demonstrated that if the preceding exclusions are applied, 
almost all infants with supraventricular t chycardia can be 
shown to have orthodromic reciprocating tachycardia through 
an accessory connection. 
There was no prospective protocol for the treatment of 
infant supraventricular tachycardia and the choice of treat- 
ment was at the discretion of the admitting pediatric ardiol- 
ogist. Digoxin was the drug of first choice for prophylaxis in 
most patients and was administered orally in a dose of 8 to 
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10/zg/kg body weight per day. Digoxin therapy was considered 
ineffective if the patient had a recurrence of sustained tachy- 
cardia after 3 days of maintenance therapy with the drug or 
had multiple or prolonged recurrent episodes of tachycardia 
requiring treatment during the period of digitalization. Fle- 
cainide was used in all patients who had recurrence of sus- 
tained tachycardia while receiving maintenance doses of 
digoxin and was given as the first choice prophylactic agent in 
the six patients who initially received intravenous flecainide to 
achieve immediate control of multiple recurrences of tachycar- 
dia. The oral preparation of flecainide used was a suspension 
containing 5 mg/ml (3M Health Care). Plasma flecainide 
concentrations were measured by using high performance 
liquid chromatography at The Poisons Unit, New Cross Hos- 
pital, London. Digoxin or flecainide treatment was withdrawn 
electively after 12 months in all patients who had had no 
recurrence of tachycardia during treatment. 
Statistical methods. Ninety-five percent confidence inter- 
vals (CI) for results expressed as proportions were taken from 
Geigy scientific tables (7). Ninety-five percent confidence 
intervals for adverse events when the numerator is zero were 
calculated as described by Hanley and Lippman-Hand (8). 
Results 
Patients. There were 39 cases of infant AV reentrant 
tachycardia between January 1986 and December 1993 (0.13/ 
1,000 live births). The age at presentation ranged from 1 to 330 
days (median 12), and only seven patients were >4 weeks of 
age. All patients had incessant tachycardia, andsix had severe 
heart failure on presentation. One patient had subaortic 
stenosis and a ventricular septal defect; the other 38 had no 
structural cardiac defects. All infants were receiving standard 
milk formula t the time of initiation of treatment, apart from 
one infant who was breast fed. Ten patients (25%) had an early 
recurrence oftachycardia, nd intravenous flecainide was used 
in a dose of 1 to 2 mg/kg for control of multiple recurrences in 
six. 
Efficacy of treatment. Digoxin was used as the primary 
agent o prevent recurrence of tachycardia in 33 patients. In 14 
patients (42%; 95% CI 25% to 61%) there was no recurrence 
of tachycardia and digoxin treatment was continued for 12 
months. In 19 patients (58%; 95% CI 39% to 75%) tachycardia 
recurred espite an adequate digoxin dose, and digoxin was 
replaced by flecainide. None of these 19 patients (95% CI 0% 
to 18%) had a recurrence oftachycardia during treatment with 
flecainide once a satisfactory dose and plasma concentration 
had been achieved. The six patients initially treated with 
intravenous flecainide were started on a regimen of oral 
flecainide as first line prophylaxis. Five of the six had no 
recurrence oftachycardia, but control continued to be difficult 
in one patient who eventually underwent successful radiofre- 
quency ablation at the age of 5 years. Overall, of the 25 patients 
treated with oral flecainide 24 (96%; 95% CI 80% to 100%) 
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Figure 1. Relation between steady state fl cainide plasma concentra- 
tion (/zg/liter) and total oral daily dose (mg/kg per day). Horizontal 
lines at 250 and 750 ~g/liter indicate the approximate lower and upper 
limits of the therapeutic range in children. 
had no recurrence of tachycardia once adequate drug plasma 
levels had been achieved. 
Drug dosage. Digoxin was administered in a dose of 8 to 
10/zg/kg per day. Plasma concentrations were not measured 
routinely and the dose was not increased if tachycardia re- 
curred in a patient receiving 10/zg/kg per day. The dose of oral 
flecainide ranged from 3.2 to 13.5 mg/kg per day and was 
adjusted in 11 patients because of either high or low plasma 
levels or inadequate control of supraventricular tachycardia. 
Flecainide was administered as a twice daily dosage, and 
plasma concentrations were measured after five doses had 
been given. Figure 1 shows the relation between the oral dose 
and the plasma concentration f flecainide and the difficulty of 
predicting this relation. Doses of 6 to 8 mg/kg per day achieved 
plasma concentrations of <300/xg/liter in two patients, 300 to 
700/xg/liter in nine and >700/zg/liter in two. Doses >8 mg/kg 
per day resulted in levels of <300/zg/liter in one patient, 300 
to 700/zg/liter in seven patients and >700/zg/liter in eight. 
Safety. No adverse events wereassociated with the use of 
oral digoxin, and there were no cases of proarrhythmia due to 
flecainide (95% CI 0% to 12%) (7). Although five patients had 
a flecainide plasma concentration > 1,000 ~tg/liter, they had no 
associated adverse effects. Two of these five patients had QRS 
prolongation that resolved after reduction of the dose. Of the 
34 patients who have been followed up for >1 year, 5 continue 
to receive oral flecainide and 2 continue to receive oral 
digoxin. 
Discuss ion 
Supraventricular tachycardia is now widely recognized as a 
primary cause of heart failure in infants and may cause 
cardiogenic shock or even death (1,9). Once the diagnosis is 
made, the immediate priority is restoration of sinus rhythm. 
The modern therapy for termination f supraventricular tachy- 
cardia is safe and effective, and either facial application of
ice-cold water or intravenous adenosine is usually recom- 
mended (3). Although most infants will experience further 
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episodes of tachycardia, it is difficult to predict the risk of 
recurrence in an individual infant. Lundberg (1) reported on 
45 infants, with recurrence of tachycardia n 25 (63%) of 40 
survivors in the absence of treatment. Benson et al. (4) 
described criteria for predicting the need for prophylactic 
treatment, but most authorities (2,3) recommend that all 
babies should be treated for the 1st 6 or 12 months of life. 
Digoxin is the conventional first line drug, b t it is difficult o 
assess its efficacy as it has not been subjected to a controlled 
clinical trial. The reported efficacy of digoxin in suppression of 
supraventricular tachycardia ranges from 44% to 61% (4,9). 
Given that approximately 40% of patients have no recurrence 
of tachycardia without treatment (1), the efficacy of digoxin is 
not impressive. In our study digoxin was "effective" in only 
42%. 
There is no consensus on treatment of infants who have 
recurrence of tachycardia while receiving digoxin. Flecainide 
has proved effective in patients with accessory connections 
and AV reentrant tachycardia, nd it has been shown to be safe 
and effective in relatively small numbers of children (10-12), 
with the exception of postoperativc patients with atrial arrhyth- 
mias. 
Supraventricular tachycardia occurs only when there is a
reentry circuit, a precipitating event and an appropriate bal- 
ance between the electrophysiologic characteristics of heAV 
node and the accessory connection. Dunnigan et l. (13) 
showed that supraventricular tachycardia in infants was pre- 
cipitated either by sinus acceleration or by an atrial premature 
beat. To prevent achycardia, a drug must suppress initiating 
events, block onduction through part of the reentry circuit or 
alter the relative conduction over components ofthe circuit to 
influence the excitable gap. The characteristics of digoxin do 
not suggest that it is likely to be very effective in preventing 
orthodromic AV reentry in infants (14). It may suppress atrial 
premature beats and can prolong AV node conduction, but it 
has no significant effect on conduction or refractoriness of the 
accessory connection. In contrast, flecainide blocks conduction 
through accessory connections (14), and it would be expected 
to be effective in i fants with orthodromic AV reentry, as it is 
in older children (10-12). 
The efficacy of flecainide in our patients contrasts with 
reports of "medically refractory" tachycardia often cited to 
justify the use of radiofrequency ablation in i fants and small 
children. However, patients with such "medically refractory" 
arrhythmia have often been treated only with digoxin and 
propranolol (15). Franklin et al. (16) recently showed that 
when a greater range of drugs is used, there are no patients in 
this age group who do not respond to treatment, and a recent 
editorial by Kugler (17) counseled against radiofrequency 
ablation in infants. 
The initial oral dose of flecainide recommended in infants 
is 6 to 8 mg/kg per day (10,18), but in our experience this may 
result in a plasma concentration aslow as 226 ~g/liter or as 
high as 1,140 /zg/liter. Little information is available on the 
pharmacokinetics of flecainide in eonates and young infants, 
and the reasons for this unpredictable dose/concentration 
relation are unknown (18,19). The target range in pediatric 
patients i  probably -300 to 700/xg/liter, and plasma concen- 
trations should bemonitored until a therapeutic concentration 
is achieved with a consistent dosage. 
Limitations of the study. Despite the absence of adverse 
effects in our infant patients treated with flecainide, the results 
of our study must be interpreted with caution. As demon- 
strated by Hanley and Lippman-Hand (8) in "If Nothing Goes 
Wrong, Is Everything All Right?," the zero numerator does 
not imply absence of risk. We can only be 95% confident that 
the risk of adverse events is no greater than 12%. 
Another limitation of our study is that we did not compare 
digoxin and flecainide directly in a controlled clinical trial and 
did not have a placebo group (20). However, comparison with 
natural history studies suggests that digoxin is relatively inef- 
fective in prophylaxis of supraventricular tachycardia n in- 
fants. We have used flecainide as our drug of second choice for 
8 years and have shown it to be effective and safe in a small 
number of infants who did not respond to treatment with 
digoxin. In our practice flecainide s now the preferred rug for 
prophylaxis of supraventricular tachycardia in infants. 
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